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Take home message 21 
There is no evidence for clinically relevant respiratory adverse effects of opioids for chronic 22 
breathlessness. 23 
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Abstract 1 
Background: Previous studies have shown that opioids can reduce chronic breathlessness in 2 
advanced disease. However, physicians remain reluctant to prescribe opioids for these patients, 3 
commonly due to fear of respiratory adverse effects.  4 
Aim: To systematically review reported respiratory adverse effects of opioids in patients with 5 
advanced disease and chronic breathlessness. 6 
Methods: Pubmed, Embase, Cochrane central register of controlled trials, CINAHL, ClinicalTrials.gov 7 
and the reference lists of relevant systematic reviews were searched. Two independent researchers 8 
screened against predefined inclusion criteria and extracted data. Meta-analysis was conducted 9 
where possible. 10 
Results: We included 63 out of 1990 articles, describing 67 studies. Meta-analysis showed an increase 11 
in partial pressure of carbon dioxide (0.27 kPa; 95% CI 0.08 to 0.45) and no significant change in 12 
partial pressure of oxygen and oxygen saturation (both p>0.05). Non-serious respiratory depression 13 
(definition variable/not stated) was described in 4/1064 patients. One cancer patient pre-treated 14 
with morphine for pain needed temporary respiratory support following nebulized morphine for 15 
breathlessness (single case study).  16 
Conclusions: We found no evidence of significant or clinically relevant respiratory adverse effects of 17 
opioids for chronic breathlessness. Heterogeneity of design and study population, and low study 18 
quality are limitations. Larger studies designed to detect respiratory adverse effects are needed.  19 
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Introduction 1 
Breathlessness is defined as “a subjective experience of breathing discomfort that consists of 2 
qualitatively distinct sensations that vary in intensity” [1]. Breathlessness is one of the most 3 
uncomfortable symptoms in patients with advanced disease [1]. In cancer, 50 to 70% of patients 4 
suffer from breathlessness, while in chronic obstructive pulmonary disease (COPD) this prevalence is 5 
as much as 56 to 98% [2, 3]. 6 
 7 
Opioids can reduce chronic breathlessness (breathlessness that persists despite optimal treatment of 8 
the underlying pathophysiology and results in disability [4]) in patients with advanced diseases [5-8]. 9 
However, while physicians are mostly willing to prescribe opioids for breathlessness in the last days 10 
or weeks of life, they are often reluctant to prescribe opioids to those earlier in their disease 11 
trajectory [9]. Their main concerns are fear of respiratory adverse effects and lack of evidence-based 12 
guidelines [10-12]. Data about respiratory adverse effects of opioids are limited and conflicting. 13 
Systematic reviews on effects of opioids on chronic breathlessness in adults with advanced life 14 
limiting disease showed no evidence for the following outcomes: respiratory depression, increase in 15 
partial pressure of arterial carbon dioxide (PaCO2), increase in partial pressure of end-tidal carbon 16 
dioxide (PetCO2), decrease in partial pressure of arterial oxygen (PaO2) or decrease in arterial oxygen 17 
saturation (SaO2) [5-8]. However, meta-analyses on these outcomes have not been conducted 18 
before. 19 
Conversely, observational studies have reported one or more cases of severe respiratory depressions 20 
in patients using opioids for breathlessness [13-16]. Most guidelines in palliative care recommend the 21 
use of opioids for chronic breathlessness [17-19]. However, guidelines in respiratory medicine, for 22 
example the recent Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines [20], are 23 
more circumspect because of possible serious adverse events and limited effectiveness. To date 24 
there is little evidence whether and to what extent opioids lead to respiratory adverse effects in 25 
patients with chronic breathlessness.  26 
 27 
The aim of this systematic review and meta-analysis was to study the occurrence of respiratory 28 
adverse effects (in particular increase of PaCO2 and PetCO2, decrease of PaO2 and SaO2, decrease in 29 
respiratory rate (RR), and occurrence of respiratory depression) in patients with advanced disease 30 
and chronic breathlessness who are treated with opioids. Respiratory adverse effects are examined 31 
in experimental studies, observational studies as well as case reports. However none of the previous 32 
reported reviews included all these study types. Therefore, to generate a full overview of the current 33 
knowledge, we included experimental studies, observational studies and case reports.   34 
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Methods 1 
A systematic review and meta-analysis was performed according to the Cochrane methodology [21]. 2 
Results are reported in accordance with the Preferred Reporting Items for Systematic Reviews and 3 
Meta-Analyses (PRISMA) statement [22]. The protocol is registered in the International Prospective 4 
Register of Systematic Reviews (PROSPERO; CRD42016033691).  5 
 6 
Search strategy 7 
The following databases were searched: PubMed, Embase on Ovid, Cochrane central register of 8 
controlled trials and CINAHL on EBSCO (inception date to March 31, 2016). Search terms comprised 9 
(dyspnoea OR synonyms) AND (opioid OR synonyms) and included both terms of controlled 10 
vocabulary and free search in title and abstract (table S1a-S1d). Furthermore, ClinicalTrials.gov was 11 
searched for ongoing or completed studies using the same search terms (May 29, 2017; table S1e). 12 
Following de-duplication, we included all original research articles such as randomized controlled 13 
trials (RCTs), non-randomized trials, case-control studies, cohort studies, chart reviews, case reports 14 
and case studies. Reference lists of three relevant systematic reviews [6-8] were searched by hand 15 
and experts in the field were contacted. We included articles in the English, Dutch, German, French 16 
and Spanish languages. When a full text article was not accessible, this was requested from the 17 
authors.  18 
 19 
Study selection 20 
For study screening, we used Endnote X7 (Thomson Reuters, Philadelphia, PA). The titles and 21 
abstracts were screened independently by two researchers (CV and either DJ, MvdB or SD) and 22 
selected based on the description of treatment for chronic breathlessness using opioids. The 23 
remaining full text articles were screened by two researchers (CV and either SD (English), DJ (German 24 
or Dutch) or LV (French or Spanish)) against all eligibility criteria: (1) participants included patients, 25 
regardless of their primary condition; (2) any opioid as intervention prescribed for breathlessness, 26 
regardless of dose or route of prescription; and (3) primary or secondary outcomes included PaCO2, 27 
PaO2, SaO2, or RR. During the screening process, we decided to also include PetCO2, occurrence of 28 
respiratory depression and breathlessness as outcomes. Any type of control group was considered. 29 
We excluded studies including only healthy subjects or studies that used an opioid in combination 30 
with other treatments and the effect of the opioid could not be distinguished. Consensus was 31 
reached by discussion. The study designs of included articles were categorised as follows: RCTs, non-32 
randomized trials (NRTs), prospective observational studies (POSs), retrospective observational 33 
studies (ROSs), and case reports (CRs). 34 
 35 
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Risk of bias 1 
Two researchers independently assessed the risk of bias on the study level (CV and either SD 2 
(English), DJ (German) or LV (French)). For the RCTs, we assessed this risk of bias regarding random 3 
sequence generation, allocation concealment, blinding, incomplete outcome data, and selective 4 
reporting using the Cochrane Risk of Bias tool [21]. The Cochrane Risk of Bias tool was also used to 5 
assess the risk of bias in NRTs. Since no control condition was included in these studies, selection 6 
bias, performance bias and detection bias were estimated as high risk of bias in all NRTs. For POSs, 7 
we assessed the risk of bias regarding selection, comparability and exposure/outcome using the 8 
Newcastle-Ottawa Quality Assessment Scale [23]. Consensus was reached by discussion. The risk of 9 
bias in ROSs and CRs was not assessed.  10 
 11 
Data collection 12 
Data were extracted by two researchers (CV and either SD (English), DJ (German) or LV (French)) 13 
using a predefined extraction form in Microsoft Excel, including data on study characteristics (design, 14 
duration, setting, in- and exclusion criteria); type of intervention (intervention, comparison, dose, 15 
mode and timing of administration); study population (sample size, age, gender, diagnosis, disease 16 
severity and use of oxygen); and outcomes (breathlessness; respiratory outcomes: PaCO2, PetCO2, 17 
PaO2, SaO2, RR and occurrence of respiratory depression; mode of assessment, missing data). When 18 
two articles appeared to describe overlapping research questions and study populations, we 19 
contacted the authors to provide more information. We recorded the baseline values and change 20 
from baseline or post-treatment scores of the respiratory outcomes. When only a description of the 21 
change from baseline was given, this was taken into account. The form was piloted on two articles of 22 
each study type and adapted as needed.  23 
 24 
Data synthesis 25 
Change from baseline measurement scores or post-treatment measurement scores, whichever was 26 
reported, were collected for the PaCO2, PetCO2, PaO2, SaO2 and RR. For the RCTs, these results were 27 
compared between the intervention and control group. For the NRTs, POSs, ROSs and CRs, the 28 
change from baseline was examined. Meta-analyses were performed using the results of RCTs; 29 
however RCTs without a placebo comparator group were not included. When both a change from 30 
baseline and a post-treatment score were reported, the post-treatment score was used in the meta-31 
analyses. Furthermore, the highest dose or latest measurement was included in the meta-analyses if 32 
multiple doses of the same opioid or repeated measurements were reported. When an RCT 33 
compared more than one opioid with placebo, the morphine group was included in the meta-34 
analysis. For measurements on exertion, the submaximal measures at a fixed time point were 35 
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included. To verify if the included RCTs showed a pooled effect of improving breathlessness, meta-1 
analysis on the effect of opioids on breathlessness was performed. These results were presented as 2 
standardized mean difference (SMD) + 95% confidence interval (CI), since different scales to measure 3 
breathlessness were used. Results of the meta-analyses on PaCO2, PetCO2, PaO2, SaO2 and RR were 4 
presented as mean difference (MD) + 95% CI, as the same scales to measure comparable outcomes 5 
were used. In all meta-analyses a random effects model was used, since the study designs were 6 
heterogeneous [21]. Results of PaO2 and PaCO2 that were reported in mmHg were converted to kPa 7 
(1 mmHg = 0.133 kPa).  8 
 9 
Some RCTs contributed more than one contrast between the opioid and control group for the same 10 
outcome (i.e. subjects were measured multiple times under comparable conditions). To account for 11 
this clustering of multiple contrasts within one study sample, we used a multilevel meta-analysis 12 
approach to determine if any within-study clustering was present. If there was evidence of within-13 
study clustering, quantified by the intraclass correlation coefficient, the results of the multilevel 14 
approach were preferred over the standard approach [24]. To examine the impact of the context of 15 
assessment (at rest or on exertion), the number of doses (single dose or multiple doses) or the route 16 
of administration (nebulized or systemic), a mixed-effects meta-regression was performed. Subgroup 17 
analyses were performed for variables which appeared to be of impact. When no impact appeared, 18 
all outcomes were analysed together.   19 
 20 
When a study assessed the occurrence of respiratory depression, the frequency of occurrence and 21 
the definition used was reported. Analysis of this outcome was descriptive.  22 
 23 
Analyses were performed using Review Manager version 5.3 (The Northern Cochrane Centre 2014, 24 
Copenhagen, Denmark) and R version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria). 25 
GRADEPro Guideline Development Tool (GDT) software was used to construct the Summary of 26 
Findings table. Results are shown per category of respiratory adverse effect. P-values of 0.05 or lower 27 
were considered statistically significant.  28 
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Results 1 
Study characteristics 2 
The search identified 1990 articles, of which 63 met the inclusion criteria (figure 1). The 63 included 3 
articles reported on 67 studies: 35 RCTs (table 1), 17 NRTs (table 1), four POSs (table S2), five ROSs 4 
(table S2) and six CRs (table S3). Six ongoing studies, four RCTs and two NRTs were identified (table 5 
S4). PaCO2, PaO2 and PetCO2 are examined in one study, SaO2 is examined in four studies and RR is 6 
examined in three studies. In one study, it is not clear which blood gases are examined. In one study 7 
the respiratory adverse effects are a primary outcome and in five studies the respiratory adverse 8 
effects are secondary outcomes. 9 
Nineteen RCTs were included in the meta-analysis on the effect of opioid treatment on 10 
breathlessness [25-42]. Eight RCTs used a visual analogue scale to examine breathlessness [25, 26, 11 
29, 35, 36, 38, 40], six RCTs used the Borg scale [27, 30-34], three RCTs used a numeric rating scale 12 
[28, 39, 41], one RCT used the dyspnoea domain of the Chronic Respiratory Questionnaire [42] and 13 
one RCT used an oxygen cost diagram [37]. The RCTs that reported post treatment scores showed 14 
effectivity of opioids in relieving breathlessness (SMD -0.42; 95% CI -0.62 to -0.21; I2 27%; Figure S1). 15 
The RCTs that reported changes from baseline were not able to show effectivity of opioids in 16 
relieving breathlessness (SMD -0.09; 95% CI -0.78 to 0.60; I2 62%; Figure S1).  17 
 18 
- insert figure 1 about here - 19 
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Table 1. Patient characteristics, study design and included outcomes of included randomized controlled trials and non-randomized trials 
Study Design N  
(% men) 
Population (n) Mean age 
(SD) (yr) 
Opioid Dose Administration  Comparison Duration Patient 
setting 
Included 
outcomes 
Abernethy, 
2003 [25] 
Cross-over 48 (73) COPD (42) 
Cancer (3) 
MND (1) 
RLD (2) 
76 (5) Morphine SR 20 mg/day Oral Placebo 4 days Outpatient SaO2, RR, 
RD 
Allard, 
1999 [43] 
Parallel 33 (42) Cancer (33) 63.3 Based on 
current 
treatment1 
50% of current dose1 Oral or 
parenteral 
25% of current 
dose1 
Single dose Inpatient RR 
Beauford, 
1993 [44] 
Cross-over 8 (88) COPD (8) 60.8 (9.1) Morphine 1, 4 or 10 mg Nebulized Placebo Single dose Outpatient PetCO2 
Bruera, 
1993  
(part 1) [26] 
Cross-over 10 (-) Cancer (10) No data Morphine Target: 150% of 
current dose (34±12 
mg) 
Parenteral Placebo Single dose Inpatient SaO2, RR 
Charles, 
2008 [38] 
Cross-over 20 (55) Cancer (20) 69 (range 48-
83) 
Hydro-
morphone1,2 
5 mg Nebulized Placebo2 Single dose Inpatient/ 
outpatient 
SaO2, RR 
Chua, 
1997 [27] 
Cross-over 12 (100) CHF (12) 65.5 (1.5) Dihydro-
codeine 
1 mg/kg body weight 
(77.4 ± 3.1 kg) 
Oral Placebo Single dose Unclear PetCO2, 
SaO2, RR 
Cuervo 
Pinna, 
2015 [28] 
Cross-over 13 (85) Cancer (13) 65.2 (10.4) Fentanyl Opioid-naïve: 200 µg 
Pre-treated: 400 µg 
Oral Placebo Single dose Unclear SaO2, RR 
Eiser, 
1991 
(part 1) [29] 
Cross-over 14 (57) COPD (14) 65 (range 49-
79) 
Diamorphine 10 or 20 mg/day Oral Placebo 2 weeks Outpatient PaCO2, 
PetCO2, 
PaO2, 
SaO2 
Eiser, 
1991 
(part 2) [29] 
Cross-over 10 (60) COPD (10) 65 (range 49-
79) 
Diamorphine 15 mg/day Oral Placebo 1 day Outpatient PaCO2, 
PaO2 
Gamborg, 
2013 [45] 
Parallel 20 (10) Cancer (20) Median 69 
(range 42-84) 
Morphine Target: 1/12 of total 
daily dose with a 
maximum of 24 mg) 
(median 8.2%) 
Oral Subcutaneous 
morphine; 60% 
of 1/12 of total 
daily dose with 
a maximum of 
14.4 mg) 
Single dose Inpatient SaO2, RR, 
RD 
Grimbert, Cross-over 12 (92) Cancer (12) 63 (range 44- Morphine 120 mg/day Nebulized Placebo 2 days Inpatient SaO2, RR 
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Table 1. Patient characteristics, study design and included outcomes of included randomized controlled trials and non-randomized trials 
Study Design N  
(% men) 
Population (n) Mean age 
(SD) (yr) 
Opioid Dose Administration  Comparison Duration Patient 
setting 
Included 
outcomes 
2004 [46] 82) 
Harris-Eze, 
1995 [30] 
Cross-over 6 (83) ILD (6) 49 (16) Morphine Target: 2.5 mg 
(mean 1.9 mg) or 5 
mg (mean 3.7 mg) 
Nebulized Placebo Single dose Outpatient PetCO2, 
SaO2 
Hui, 
2014 [39] 
Parallel 20 (45) Cancer (20) 55 (range 27-
75) 
Fentanyl3 30-350 µg4 Parenteral Placebo Single dose Outpatient SaO2, RR 
Jankelson, 
1997 [31] 
Cross-over 16 (69) COPD (16) 69 (range 61-
85) 
Morphine 20 or 40 mg Nebulized Placebo Single dose Inpatient SaO2 
Jensen, 
2012 [32] 
Cross-over 16 (58) COPD (16) 70.5 (2.3) Fentanyl 50 µg Nebulized Placebo Single dose Unclear PetCO2, 
SaO2, RR, 
RD 
Johnson, 
2002 [47] 
Cross-over 10 (100) CHF (10) 67 (range 45-
85) 
Morphine 10-20 mg/day Oral Placebo 4 days Inpatient PaCO2, 
PaO2, 
SaO2, RR 
Krajnik, 
2009 [48] 
Parallel 10 (40) Cancer (10) 55.5 (range 
39-73) 
Morphine 5 mg Nebulized 2 types of 
nebulization 
Single dose Inpatient PaCO2, 
PaO2, 
SaO2 
Light, 
1989 [33] 
Cross-over 13 (100) COPD (13) 65.9 (range 
58-70) 
Morphine 0.8 mg/kg Oral Placebo Single dose Unclear PaCO2, 
PaO2, 
SaO2, RR 
Light, 
1996 [34] 
Cross-over 7 (100) COPD (7) 66.4 (3.3) Morphine 30 mg Oral Placebo Single dose Unclear PetCO2 
Masood, 
1995 [49] 
Cross-over 12 (100) COPD (12) 66.3 (7.0) Morphine N: 10 and 25 mg 
P: 1 and 2.5 mg 
Nebulized and 
parenteral 
Placebo Single dose Inpatient SaO2, RR 
Mazzocato, 
1999 [40] 
Cross-over 9 (66) Cancer (9) 73 (range 66-
83) 
Morphine 5 mg (or 150% of 
pre-treatment dose) 
Parenteral Placebo Single dose Inpatient SaO2, RR, 
RD 
Munck, 
1990  
(part 2) [50] 
Cross-over 21 (-) COPD (21) Median 67 
(range 50-78) 
Codeine 60 mg/day Oral 1 gram 
paracetamol 
7 days Inpatient PaCO2, 
PaO2, 
SaO2, RR 
Natalini, 
2011 [51] 
Cross-over 13 (43) Trauma (3) 
COPD (3) 
Pneumonia (3) 
Stroke (2) 
Median 78 
(IQR 73-82) 
Remifentanyl 0.05 µg/kg/min Parenteral Placebo Single dose Inpatient PaCO2, 
PaO2, RR 
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Table 1. Patient characteristics, study design and included outcomes of included randomized controlled trials and non-randomized trials 
Study Design N  
(% men) 
Population (n) Mean age 
(SD) (yr) 
Opioid Dose Administration  Comparison Duration Patient 
setting 
Included 
outcomes 
Epilepsy (1) 
Peritonitis (1) 
Navigante, 
2010 [52] 
Parallel 63 (-) Cancer (31) Median 55 
(range 30-80) 
Morphine1 22.5 (4.12) mg Oral Midazolam 5 days Outpatient SaO2 
Noseda, 
1997 [35] 
Cross-over 17 (76) COPD (12) 
IPF (1) 
Cancer (3) 
CHF (1) 
69 (11) Morphine 10 or 20 mg Nebulized Placebo Single dose Inpatient SaO2, 
RR 
Otulana, 
2004 
(phase 3) 
[53] 
Cross-over 19 (-) Asthma (19) Range 19-64 Morphine 2.2, 4.4 or 8.8 mg Nebulized 3 doses Single dose Unclear RR 
Oxberry, 
2011 [41] 
Cross-over 35 (86) CHF (35) 70.2 (11.1) Morphine 
Oxycodone 
20 mg/day 
10 mg/day 
Oral Placebo 4 days Outpatient SaO2, RR 
Poole, 
1998 [42] 
Cross-over 16 (69) COPD (16) 70.7 (6.4) Morphine SR Target: 40 mg 
(mean 25 mg) 
Oral Placebo 6 weeks Outpatient SaO2 
Rice, 
1987 [54] 
Cross-over 11 (100) COPD (11) Range 59-79 Codeine 120 mg Oral Promethazine 1 month Unclear PaCO2, 
PaO2 
Robin, 
19865 [55] 
Cross-over 1 (0) OLD 63 Hydro-
morphone 
12 mg/day Rectal Placebo 24 hours Outpatient PaCO2, 
PaO2 
Schonhofer, 
1998 [56] 
Cross-over 20 (55) Lung 
emphysema (20) 
68.5 (6.8) Morphine SR Target: 90 mg 
(mean 49 mg) 
Oral Usual care 10 days Inpatient PaCO2, 
PaO2, RD 
Shohrati, 
2012 [36] 
Parallel 40 (100) COPD (40) No data Morphine 1 mg/day Nebulized Placebo 5 days Inpatient RR 
Smith, 
2009 [57] 
Cross-over 2 (0) Cancer (1) 
Unclear (1) 
49 & 59 Fentanyl 25 µg Nebulized Placebo Single dose Inpatient SaO2, RR 
Williams, 
2003 [58] 
Cross-over 16 (94) CHF (16) 61 (8.8) Diamorphine 1 or 2 mg Parenteral Placebo Single dose Unclear PetCO2, 
RR 
Woodcock, 
1982 [37] 
Cross-over 16 (-) COPD (16) No data Dihydro-
codeine 
90 or 180 mg/day Oral Placebo  2 weeks Outpatient PaCO2, 
PaO2 
Allcroft, 
2013 [59] 
Non-
randomized 
13 (62) COPD (13) Median 78 
(range 68-89) 
Morphine 10 mg/day Oral - 4 days Inpatient/ 
outpatient 
PetCO2, 
SaO2, RR, 
RD 
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Table 1. Patient characteristics, study design and included outcomes of included randomized controlled trials and non-randomized trials 
Study Design N  
(% men) 
Population (n) Mean age 
(SD) (yr) 
Opioid Dose Administration  Comparison Duration Patient 
setting 
Included 
outcomes 
Boyd, 
1997 [60] 
Non-
randomized 
15 (47) Cancer (15) 73 (range 62-
85) 
Morphine 20 mg/day or 130% 
of pre-treatment  
dose 
Oral - 7-10 days Inpatient/ 
outpatient 
RR 
Bruera, 
1990 [61] 
Non-
randomized 
20 (55) Cancer (20) 64 (17) Morphine 5 mg or 2.5 times 
pre-treatment dose 
Parenteral - Single dose Inpatient PetCO2, 
SaO2, RR 
Bruera, 
1993 
(part 2) [26] 
Non-
randomized 
45 (-) Cancer (45) No data Morphine3 Same dose as for 
pain treatment 
Parenteral - Total of 312 
doses 
Unclear RD 
Clemens, 
2007 [62] 
Non-
randomized 
25 (44) Cancer (25) 65.5 (15.1) Morphine6 
Hydro-
morphone6 
8.2 (7.5) mg MED 
19.5 (1.8) mg MED 
No data - Single dose Inpatient SaO2, RR, 
RD 
Clemens, 
2008.1 [63] 
Non-
randomized 
6 (67) ALS (6) 57.0 (6.9) Morphine1 6.3 (7.0) mg Oral - Single dose Inpatient PaCO2, 
SaO2, RR, 
RD 
Clemens, 
2008.2 [64] 
Non-
randomized 
14 (57) Cancer (14) Median 67 
(range 40-84) 
Hydro-
morphone1 
2.5 (1.8) mg Oral - Single dose Inpatient PaCO2, 
SaO2, RR, 
RD 
Clemens, 
2008.3 [65] 
Non-
randomized 
27 (48) Cancer (25) 
ALS (2) 
Range 40-90 Morphine1,6 
Hydro-
morphone1,6 
2.5-20.0 mg 
0.5-6.0 mg 
Oral - Single dose Inpatient PaCO2, 
SaO2, RR, 
RD 
Clemens, 
2009 [66] 
Non-
randomized 
46 (54) Cancer (46) Range 40-90 Morphine1,6 
Hydro-
morphone1,6 
2.5-20 mg 
1-6 mg 
Oral - Single dose Inpatient PaCO2, 
SaO2, RR, 
RD 
Clemens, 
2011 [67] 
Non-
randomized 
26 (54) Cancer (26) 66.0 (13.6) Morphine1 
Hydro-
morphone1 
8.4 (7.2) mg 
4 (4.7) mg 
Oral - Single dose Inpatient PaCO2, 
SaO2, RR, 
RD 
Cohen, 
1991 [68] 
Non-
randomized 
8 (-) Cancer (8) 61.9 (range 
50-79) 
Morphine1 120 mg/day Parenteral - 60 hours Unclear PaCO2, 
PaO2, RR 
Coyne, 
2002 [69] 
Non-
randomized 
35 (43) Cancer (33) 
Pulmonary 
embolism (1) 
AIDS (1) 
56 Fentanyl 25 µg Nebulized - Single dose Inpatient SaO2, RR 
Currow, Non- 83 (64) COPD (45) 74.6 (9.1) Morphine Target: 10-30 mg Oral - Target 3 Outpatient RD 
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Table 1. Patient characteristics, study design and included outcomes of included randomized controlled trials and non-randomized trials 
Study Design N  
(% men) 
Population (n) Mean age 
(SD) (yr) 
Opioid Dose Administration  Comparison Duration Patient 
setting 
Included 
outcomes 
2011 [70] randomized Cancer (24) 
ILD (10) 
Other (4) 
Phase II: 16.5 (8) mg 
Phase IV: 14.0 (6.3) 
mg 
months 
(mean 142 
days) 
Gauna, 
2008 [71] 
Non-
randomized 
4 (50) COPD and PF (2) 
Cancer (2) 
Range 52-85 Fentanyl3 200-400 µg Oral - Single dose Inpatient SaO2, RR 
Munck, 
1990 
(part 1) [50] 
Non-
randomized 
21 (-) COPD (21) Median 67 
(range 50-78) 
Codeine 60 and 120 mg Oral - Single dose Outpatient PaCO2, 
PaO2, 
SaO2, RR, 
RD 
Otulana, 
2004 
(phase 4) 
[53] 
Non-
randomized 
6 (-) Asthma (6) No data Morphine 17.6 mg Nebulized - Single dose Unclear RR 
Tanaka, 
1999 [72] 
Non-
randomized 
15 (53) Cancer (15) Median 61 
(range 42-76) 
Morphine 20 mg Nebulized - Single dose Inpatient SaO2, RR, 
RD 
ALS: amyotrophic lateral sclerosis; CHF = congestive heart failure; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; IQR = interquartile range; 
MND: motor neuron disease; OLD = obstructive lung disease; PaCO2: partial pressure of arterial carbon dioxide; PaO2: partial pressure of arterial oxygen; PetCO2: partial pressure of end-tidal carbon 
dioxide; PF: pulmonary fibrosis; RD: respiratory depressions; RLD: restrictive lung disease; RR: respiratory rate; SaO2: arterial oxygen saturation; SD = standard deviation  
1 application of opioid for breakthrough breathlessness possible 
2 application of placebo for breakthrough breathlessness possible 
3 intervention prescribed for breakthrough breathlessness 
4 Based on dose of current opioids for breakthrough breathlessness  
5 This study is a single-patient RCT, which was terminated after the run in phase and the placebo arm. Data are therefore based on the run-in arm. 
6 choice of dose or type of opioid depended on general condition of the patient 
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Risk of bias 1 
As shown in table S5, the risk of bias of the RCTs was estimated as low risk or unclear risk in most 2 
studies. Other sources of bias were assessed as high in 43% of the studies, mainly because of the 3 
absence of a wash-out period in cross-over trials. Table S6 shows the risk of bias of the NRTs. 4 
Selection bias, performance bias and detection bias were estimated as high risk of bias, as no control 5 
condition was included in these studies. In the other categories, the risk of bias was assessed as low 6 
in most studies. The POSs were graded with three to six out of eight stars due to comparability and 7 
representativeness of cohorts (table S7).  8 
 9 
Effect on outcomes of respiratory adverse effects 10 
The effect of opioid treatment on outcomes of respiratory adverse effects is shown in tables S2, S3, 11 
S8 and S9. A summary of the effects of the RCTs included in the meta-analyses is presented in the 12 
Summary of Findings table (table 2). Since none of the intraclass correlation coefficients of 13 
comparisons within RCTs were significantly different from 0 and therefore the effect of clustering on 14 
the outcomes was negligible for RCTs that contributed more than one contrast for a single outcome 15 
measure, the results are analysed using regular meta-analyses instead of three-level meta-analyses. 16 
Most of the included RCTs were cross-over trials and we included both parallel and cross-over trials 17 
in the meta-analyses together. Results of 12 RCTs could not be included in the meta-analyses 18 
because they compared opioid treatment to other than placebo (treatment with another substance 19 
[50, 52, 54], another dose or route of administration [43, 45, 48, 53], or usual care [56] [Table S8]). 20 
Results of 7 RCTs could not be included in the meta-analyses because they reported their outcomes 21 
as median scores [51], did not report the outcomes per treatment arm [46, 49], or reported the 22 
outcome only in qualitative wording [30, 44, 55, 57] (Table S8). 23 
 24 
Effect on PaCO2 25 
The effect of opioid treatment on PaCO2 was assessed in nine RCTs [29, 33, 37, 50, 51, 54-56], five of 26 
which could be included in the meta-analysis [29, 33, 37, 51]. The meta-analysis showed that 27 
treatment with opioids increased PaCO2 (MD 0.27; 95% CI 0.08 to 0.45; I2 0%, see figure 2a). The 28 
meta-regression revealed no influence from the context of assessment (p=0.437; however there was 29 
only one RCT during exercise) or the number of doses (p=0.507) on the PaCO2. Route of 30 
administration was not taken into account, since all RCTs administered the opioid systemically. 31 
One RCT examined the effect of opioids on PaCO2 during exercise [33]. The difference between the 32 
intervention and control group after administration of morphine was statistically significant at 33 
maximal exercise (5.8 and 5.1 kPa respectively, p<0.001). The effect on PaCO2 was also assessed in 34 
seven NRTs [50, 63-68]. One NRT found a significant increase in PaCO2 [68]. Finally, the effect on 35 
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PaCO2 was assessed in one ROS [73] and one CR describing two cases [74]. In both studies the opioids 1 
were nebulized. The opioids were prescribed as single dose or up to 15 days. In all studies, PaCO2 was 2 
measured at rest. None of these studies showed a significant effect of opioid treatment on PaCO2. 3 
 4 
Effect on PetCO2 5 
The effect of opioid treatment on PetCO2 was assessed in seven RCTs [27, 29, 30, 32, 34, 44, 58], five 6 
of which could be included in the meta-analysis [27, 29, 32, 34, 58]. The meta-analysis showed a non-7 
significant increase of the PetCO2 (MD 0.13; 95% CI -0.02 to 0.27; I2 0%, see figure 2b). The RCT by 8 
Light et al. [34] had a low variance compared to the other studies and consequently a high weight in 9 
the analysis. Therefore, the meta-analysis was repeated, but with weighing based on the sample size. 10 
The effect on PetCO2 was still not significant (MD 0.13; 95% CI -0.11 to 0.37; I2 0%). The meta-11 
regression revealed no influence from the context of assessment (p=0.375), the number of doses 12 
(p=0.679) or the route of administration (p=0.473) on the PetCO2. 13 
The effect on PetCO2 was also assessed in two NRTs [59, 61]. These studies reported no significant 14 
change in PetCO2 [59, 61]. 15 
 16 
- insert figure 2 about here - 17 
 18 
Effect on PaO2 19 
The effect of opioid treatment on PaO2 was assessed in nine RCTs [29, 33, 37, 50, 51, 54-56], four of 20 
which could be included in the meta-analysis [29, 33, 37]. The meta-analysis showed a non-significant 21 
decrease of the PaO2 (MD -0.26; 95% CI -0.68 to 0.15; I2 0%, see figure 3a). The meta-regression 22 
revealed no influence from the context of assessment (p=0.420; however only one RCT during 23 
exercise) or the number of doses (p=0.815) on the PaO2. Route of administration was not taken into 24 
account, since all RCTs administered the opioid systemically. 25 
One RCT examined the effect of opioids on PaO2 during exercise [33]. The difference between the 26 
intervention and control group after administration of morphine was statistically significant at 27 
maximal exercise (8.8 and 9.6 kPa respectively, p<0.05). The effect on PaO2 was also assessed in two 28 
NRTs [50, 68]. One NRT found a significant decrease in PaO2 [68]. Finally, the effect on PaO2 was 29 
assessed in one CR describing two cases [74]. In this study the opioids were nebulized for up to 15 30 
days. PaO2 was measured in rest. This study showed no significant effect of opioid treatment on 31 
PaO2. 32 
 33 
Effect on SaO2 34 
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The effect of opioid treatment on SaO2 was assessed in 24 RCTs [25-33, 35, 38-42, 44-46, 48-50, 52, 1 
53, 57], 14 of which could be included in the meta-analysis [26-33, 35, 38-42]. The meta-analysis 2 
showed that SaO2 decreased after opioid use (MD -0.41; 95% CI -0.73 to -0.08; I2 0%, see figure 3b). 3 
The RCT by Chua et al. [27] was the only RCT showing a significant difference in SaO2 between the 4 
intervention and control group at rest (99.3% and 100% respectively, P=0.03). This RCT reported a 5 
variance of 0 in the control group in rest and consequently had a high weight in the analysis. 6 
Therefore, as a sensitivity analysis the meta-analysis was repeated, but with weighing based on the 7 
sample size. The effect on SaO2 was no longer significant (MD -0.31; 95% CI -1.06 to 0.45; I2 0%). The 8 
meta-regression revealed no influence from the context of assessment (p=0.730), the number of 9 
doses (p=0.165) or the route of administration (p=0.538) on the SaO2. 10 
Furthermore, the effect of opioids on SaO2 was assessed in 12 NRTs [50, 59, 61-67, 69, 71, 72]. One 11 
NRT showed a significant decrease in SaO2 from 93 to 92% [50] after a single dose of 120 mg codeine. 12 
However, this decrease was temporary and not clinically relevant. Finally, the effect of opioids on 13 
SaO2 was assessed in two POSs [75, 76], two ROSs [73, 77] and three CRs describing seven cases [74, 14 
78, 79]. In these studies the opioids were administered systemically (n=3), nebulized (n=2) or via 15 
unknown route (n=1). The opioids were prescribed as single dose or as repeated doses up to three 16 
months. In all studies, SaO2 was measured at rest. None of these studies showed a significant effect 17 
of opioid treatment on SaO2. In two RCTs [25, 44] and one NRT [59] SaO2 was measured, but no 18 
outcome data were reported.  19 
 20 
Effect on RR 21 
The effect of opioid treatment on RR was assessed in 23 RCTs [25-28, 30, 32, 33, 35, 36, 38-41, 43, 22 
45-47, 49-51, 53, 57, 58], 13 of which could be included in the meta-analysis [25, 26, 30, 32, 33, 35, 23 
36, 38-41, 47, 58]. The meta-analysis showed that treatment with opioids significantly decreased the 24 
RR (MD -1.10; 95% CI -1.49 to -0.71; I2 0%, see figure 3c). The RCT by Shohrati et al. [36] was the only 25 
RCT showing a significant difference in change in RR between the intervention and control group (-26 
1.5 and -0.1 respectively, P<0.001). This RCT had a low variance compared to the other studies and 27 
consequently a high weight in the analysis. Therefore, the meta-analysis was repeated, but with 28 
weighing based on the sample size. The effect on RR was no longer significant (MD -0.58; 95% CI -29 
1.72 to 0.56; I2 0%). The heterogeneity among the RCTs describing post-treatment scores was 0%. 30 
The meta-regression revealed no influence from the context of assessment (p=0.496), the number of 31 
doses (p=0.904) or the route of administration (p=0.139) on the RR. 32 
The effect on RR was also assessed in 15 NRTs [50, 53, 59-69, 71, 72]. These studies also showed that 33 
opioids caused no significant change in RR. Finally, the effect on RR was assessed in three POSs [75, 34 
76, 80], two ROSs [73, 77] and four CRs describing ten cases [74, 78, 79, 81]. In these studies the 35 
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opioids were administered systemically (n=4), nebulized (n=4) or via unknown route (n=1). The 1 
opioids were prescribed as single dose or as repeated doses up to three months. In all studies, SaO2 2 
was measured at rest. These studies also showed that opioids caused no significant change in RR. In 3 
two RCTs [28, 50] and one NRT [50], RR was measured, but no outcome data were reported. 4 
 5 
- insert figure 3 about here - 6 
 7 
Occurrence of respiratory depression 8 
The occurrence of respiratory depressions was reported in five RCTs [25, 32, 40, 45, 56], eleven NRTs 9 
[26, 50, 59, 62-67, 70, 72], two POSs [14, 75], three ROSs [15, 82, 83] and four CRs describing ten 10 
cases [13, 74, 79, 84]. Of these 25 studies, eleven studies defined respiratory depression [13, 14, 40, 11 
63-67, 72, 75, 84]. Definitions were based on an increase in PaCO2 of >0.5 kPa or to more than 6.0 12 
kPa, a decrease in RR of >10% or to less than 10 breaths/minute and a decrease in SaO2 of >5% or to 13 
less than 90%. Hu et al. [14] observed a case of respiratory depression (defined as decrease in RR to 14 
<10 breaths/minute) in one patient with terminal cancer both at the beginning of the POS and two 15 
days prior to death. Kawabata et al. [15] reported three patients experiencing a respiratory 16 
depression (no definition given), which were not serious. It was not stated if these patients were 17 
treated for pain or breathlessness. Lang and Jedeikin [13] described a case of respiratory depression 18 
(defined as RR of 4-5 breaths/minute, very poor respiratory effort and minimal wheezing over both 19 
lung fields) after administration of 4 mg nebulized morphine and 4 mg dexamethasone for 20 
breakthrough breathlessness in a patient already using 10 mg oral slow-release morphine three 21 
times per day and 10 mg oral immediate release morphine when required for cancer-related pain. 22 
 23 
Quality of the evidence 24 
The quality of the evidence was assessed as very low to moderate for the different outcomes (table 25 
2). Only RCTs were included in this assessment. For all outcomes, the majority of the RCTs were small 26 
with insufficient power to assess respiratory adverse events and the quality was therefore 27 
downgraded. Furthermore, limitations in the design and implementation were observed. In several 28 
RCTs, patients who were pre-treated with opioids were included, which had a negative effect on the 29 
quality of the evidence. Finally, only a small number of RCTs included assessment of PaCO2 and PaO2. 30 
 31 
Table 2. Summary of findings 
Opioids compared to placebo for patients with chronic breathlessness due to advanced disease 
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Patient or population: patients with chronic breathlessness due to advanced disease  
Setting: inpatient and outpatient setting  
Intervention: opioids  
Comparison: placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Quality of 
the 
evidence 
(GRADE)  
Comments 
Risk with 
placebo 
Risk with opioids 
PaCO2 The mean 
PaCO2 
ranged 
from 4.4 to 
5.9 kPa  
The mean PaCO2 in the 
intervention group was 
0.27 kPa higher (0.08 kPa 
higher to 0.45 kPa higher)  
-  146 
(5 RCTs)  
⨁◯◯◯ 
VERY LOW 
a,b,c 
 
PetCO2: PTS The mean 
PetCO2: PTS 
ranged 
from 4.13 
to 5.79 kPa  
The mean PetCO2: PTS in 
the intervention group 
was 0.10 kPa higher (0.13 
kPa lower to 0.34 kPa 
higher)  
-  156 
(4 RCTs)  
⨁◯◯◯ 
VERY LOW 
a,b,c 
 
PetCO2: CFB  The mean 
PetCO2: 
CFB was -
0.05 kPa  
The mean PetCO2: CFB in 
the intervention group 
was 0.14 kPa higher (0.05 
kPa lower to 0.33 kPa 
higher)  
-  14 
(1 RCT)  
⨁⨁◯◯ 
LOW b,c 
 
PaO2  The mean 
PaO2 
ranged 
from 9.0 to 
10.4 kPa  
The mean PaO2 in the 
intervention group was 
0.26 kPa lower (0.68 kPa 
lower to 0.15 kPa higher)  
-  118 
(4 RCTs)  
⨁◯◯◯ 
VERY LOW 
a,b,c 
 
SaO2: PTS  The mean 
SaO2: PTS 
ranged 
from 84 to 
100 %  
The mean SaO2: PTS in the 
intervention group was 
0.47 % lower (0.87% 
lower to 0.07% lower)  
-  312 
(10 RCTs)  
⨁◯◯◯ 
VERY LOW 
a,b,d 
 
SaO2: CFB The mean 
SaO2: CFB 
ranged 
from -0.3 
to 2.1 %  
The mean SaO2: CFB in 
the intervention group 
was 0.29 % lower (0.85% 
lower to 0.26% higher)  
-  196 
(4 RCTs)  
⨁⨁◯◯ 
LOW b,c 
 
RR: PTS  The mean 
RR: PTS 
ranged 
from 18.6 
to 40.0  
The mean RR: PTS in the 
intervention group was 
0.86 lower (1.71 lower to 
0.02 lower)  
-  328 
(9 RCTs)  
⨁◯◯◯ 
VERY LOW 
a,b,d 
 
RR: CFB The mean 
RR: CFB 
ranged 
from -4.2 
to 0.0  
The mean RR: CFB in the 
intervention group was 
0.80 lower (1.83 lower to 
0.24 higher)  
-  208 
(4 RCTs)  
⨁◯◯◯ 
VERY LOW 
b,c,d 
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Table 2. Summary of findings 
Opioids compared to placebo for patients with chronic breathlessness due to advanced disease 
Patient or population: patients with chronic breathlessness due to advanced disease  
Setting: inpatient and outpatient setting  
Intervention: opioids  
Comparison: placebo  
Outcomes Anticipated absolute effects* (95% CI)  Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Quality of 
the 
evidence 
(GRADE)  
Comments 
Risk with 
placebo 
Risk with opioids 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI).  
 
CFB: change from baseline; CI: Confidence interval; MD: Mean difference; PTS: post-treatment scores  
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to 
the estimate of the effect, but there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different 
from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be 
substantially different from the estimate of effect  
 
a. There were limitations in design and implementation, which suggest a risk of bias  
b. The majority of studies were not powered to detect changes in this outcome  
c. A small amount of studies included  
d. Patients who were pre-treated with opioids were included 
  1 
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Discussion 1 
Main findings 2 
This systematic review on occurrence of respiratory adverse effects following opioid treatment for 3 
breathlessness shows a great heterogeneity of treatment regimens and patient populations. Given 4 
this heterogeneity, we found no evidence that clinically relevant respiratory adverse effects are to be 5 
expected in patients with breathlessness who are treated with opioids, while included studies 6 
confirmed previous reports of opioid-related benefit for breathlessness. This suggests that clinicians’ 7 
fears of respiratory obtundation with the use of low dose opioids seem to be unfounded.  8 
 9 
The meta-analysis showed an increase in PaCO2 of 0.27 kPa (0.09 to 0.46). Although this increase is 10 
statistically significant, it is not considered to be clinically relevant [85]. Indeed, the pooled mean (SD) 11 
PaCO2 was 5.35 (1.08) kPa, so the mean difference in PaCO2 was only 25% of the SD. However, few 12 
RCTs reported on PaCO2 and the quality of this evidence is assessed as very low. One NRT reported a 13 
significant deterioration of blood gases, but the participants received 120 mg parenteral morphine 14 
per day [68]. Given that 20% to 40% of oral morphine is bioavailable, this represents a much higher 15 
dose than the oral morphine doses required in the dose titration study (10-30 mg oral morphine per 16 
day) [70] or the oral morphine repeat dose trials (20 mg oral morphine per day) [25, 41, 47]. The 17 
meta-analyses showed a significant decrease in SaO2 of 0.41% (0.73 to 0.08) and RR of 1.10 18 
times/minute (1.49 to 0.71). However, in both analyses one study had a high weighting due to a small 19 
variance. The statistical significance disappeared when the analyses were repeated weighted on 20 
sample size. In four cases, a diagnosis of respiratory depression was made during the study, but the 21 
definition was poorly stated. In three occasions the indication and dose were not clear [15]. In the 22 
fourth case, respiratory depression occurred in a patient with advanced metastatic cancer pre-23 
treated with opioids. The additive effect of both treatments, leading to a high dose of morphine, may 24 
have led to respiratory depression [13]. It is notable that no cases of respiratory depression were 25 
noted in the context of RCTs, with their close monitoring. Neither the meta-analyses of PetCO2, PaO2, 26 
SaO2 and RR nor the studies that were not included in the meta-analyses showed a significant 27 
deterioration of these outcomes. The meta-regression did not provide a significant effect for the 28 
context of assessment (at rest or on exertion), the number of doses (single dose or multiple doses) or 29 
the route of administration (nebulized or systemic), which is surprising especially for the route of 30 
administration. Previous reviews have reported a different effect of opioids on breathlessness when 31 
administered systemically or nebulized [5, 6]. The results of this meta-regression might be related to 32 
small effects within the included studies and the fact that only six studies included in the meta-33 
analysis used nebulized opioid.  34 
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Six ongoing studies were identified. Three of them only examine a single or double dose of opioids 1 
and are therefore not able to say anything about the long-term effect. Of the three other studies, 2 
two have respiratory adverse effects as a secondary outcome and the sample size calculation will 3 
therefore probably not be based on this outcome. Only the MORDYC study primary focusses on 4 
respiratory adverse effects and based the sample size calculation on the PaCO2 [85]. This study will 5 
add valuable information about the occurrence of respiratory adverse effects. 6 
Our findings are consistent with other reviews on opioids for chronic breathlessness [5, 6, 86] and 7 
episodic breathlessness [87]. These reviews included RCTs [5, 6, 86, 87], NRTs [6, 86] and CRs [87]. 8 
The authors of these reviews also found no clinically relevant effect on blood gases or oxygen 9 
saturation, or respiratory depression after treatment with different types of opioids in patients with 10 
advanced disease. In hypoxic patients with cancer, an improvement of SaO2 was reported [6]. 11 
However, these reviews only included 39 studies and meta-analyses could not be performed due to 12 
limited results on respiratory adverse effects. Furthermore, the focus of these reviews was on the 13 
effect of opioid treatment on breathlessness and search terms for respiratory adverse effects were 14 
not included.  15 
 16 
Limitations of the included studies 17 
First, the risk of bias of the included studies was often difficult to estimate. The outcomes of interest 18 
in the current review were secondary outcomes in the majority of the included studies and therefore 19 
the method of outcome assessment was often not described. The method of randomization or 20 
allocation concealment was inadequately described in most studies. Since it was difficult to score the 21 
risk of bias and to set a cut-off point, we did not include a sensitivity analysis including only the 22 
studies with a low risk of bias. Second, there was great heterogeneity in the dosing regimens and 23 
comparators used. The prescribed doses ranged between the studies, with eight studies prescribing 24 
high doses of opioids. In 34 experimental studies, one observational study and seven cases, only a 25 
single dose of opioids was prescribed, so the long-term effect was not assessed. Seven RCTs did not 26 
include a placebo group, but used different doses, other medication or usual care as comparator. 27 
Third, the patient populations were heterogeneous. In some studies patients had to be opioid-naïve, 28 
but not in others – where patients could continue opioids for pain or where the dose of the study 29 
medication was based on current analgesic treatment. Fourth, the included studies had a small 30 
sample size. The experimental studies included one to 83 participants with only six studies including 31 
a sample size of 30 or more participants per treatment group. These studies included outcomes of 32 
respiratory adverse effects, but were underpowered to properly assess a change in these outcomes. 33 
The observational studies used larger sample sizes, but only a proportion of these patients received 34 
opioids for breathlessness. In some studies, the results accounted for the entire group, making it 35 
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impossible to draw conclusions for the subgroup of our interest. Fifth, the definition of respiratory 1 
depression differed between studies. The most reliable assessment of respiratory depression is 2 
based on the PaO2 and PaCO2. Measurement of SaO2 is less reliable [88]. Some authors included RR 3 
as a measure of respiratory depression, because this is easier to estimate. Only eleven studies 4 
defined respiratory depression and eight used a decrease in SaO2 as part of the definition. Only four 5 
also included an increase of PaCO2. Finally, five studies mentioned the assessment of respiratory 6 
outcomes in their method section, but didn’t include the results (n=3) or only reported the baseline 7 
data (n=2). Furthermore, 25 studies reported on the occurrence of respiratory depression but only 8 
nine of them mentioned the assessment of respiratory depression in their methods section. 9 
Therefore, it is not known if a respiratory depression occurred in one of the remaining 42 studies.  10 
 11 
Strengths and limitations of the current review 12 
Our study has several strengths. We included several study types; although RCTs yield the most 13 
reliable evidence, observational studies and CRs are closer to daily clinical practice. Furthermore, we 14 
included studies that were published in five languages. Because of the large number of included 15 
studies, we were able to present the current knowledge of six different outcomes of respiratory 16 
adverse effects and were able to perform meta-analyses on five. This provides an overall estimate of 17 
the effect of opioid treatment on these outcomes.  18 
Our review also has several limitations. First, we only searched four databases. Due to publication 19 
bias, we might have failed to identify negative results. However, we also searched one trial register, 20 
sought expert opinions and hand-searched the reference lists of important reviews in the field of 21 
opioid treatment for chronic breathlessness. We identified a large number of studies, decreasing the 22 
chance that we missed important studies. Second, several RCTs could not be included in the meta-23 
analyses because of reasons as discussed before. Third, we combined results from studies with 24 
different contexts of assessment, different number of doses and different route of administration; 25 
however, this was done only after the meta-regression which did not yield evidence that these 26 
moderators had an effect on the outcome. The number of studies used for this analysis was in some 27 
cases very low, making the power to detect effects questionable. However, due to the robustness of 28 
the results (i.e. no single moderator was significant in any of the analyses), we combined all 29 
measures to be pooled. Fourth, the patient populations were too diverse to specify the results for 30 
different populations. We primarily expect that patients with COPD and chronic respiratory failure 31 
are more at risk for respiratory adverse effects than for example patients with cancer or heart failure. 32 
Most of the studies included patients with a specified primary diagnosis (n=54), of which 16 studies 33 
only included patients with COPD. However, from these populations it is not known which patients 34 
experienced chronic respiratory failure. Fifth, we used the Cochrane Risk of Bias tool to assess the 35 
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risk of bias in RCTs and NRTs. This tool is designed to use in RCTs, but there was no appropriate 1 
alternative to use in NRTs. After assessment of the risk of bias was completed, the Risk Of Bias In 2 
Non-randomised Studies – of Interventions (ROBINS-I) tool was published [89]. This might have been 3 
a better tool to assess the risk of bias in NRTs and can be used in future studies. Finally, we included 4 
both cross-over trials and parallel trials in the meta-analysis together and analysed the cross-over 5 
trials as if they were parallel trials. This might result in a unit of analysis error, leading to an 6 
underweighting of the cross-over trials. Since only two studies included in the meta-analyses of SaO2 7 
and RR were parallel trials and the remaining studies were cross-over trials, we assume this influence 8 
to be negligible.  9 
 10 
Implications for clinical practice and future research 11 
Patients are willing to consider opioid treatment for chronic breathlessness, despite the occurrence 12 
of adverse effects, and report improvement of quality of life and relief of breathlessness as their 13 
main reasons [12]. However, physicians remain reluctant to prescribe opioids for chronic 14 
breathlessness, among other things because of fear of adverse clinical outcomes [9-12]. A recent 15 
large observational study of older adults with COPD by Vozoris et al. [90] showed an association 16 
between new prescription of opioid and a small, but statistically significant increase in 30 day 17 
mortality and emergency visits. However, palliative care patients (and thus those who form the main 18 
group for whom opioids would be prescribed for breathlessness) were excluded and other 19 
differences between patients with and without opioid use might explain these findings. In contrast, a 20 
registry study of people with advanced COPD on long-term oxygen therapy, with four years follow 21 
up, found no association with either hospital admission or survival in people taking 30 mg or less of 22 
oral morphine per day [91]. 23 
This review has shown that the current evidence on respiratory adverse effects of opioid treatment 24 
in chronic breathlessness is inconsistent and heterogenic. Only one serious episode of respiratory 25 
depression is described, and that in the context of high dose opioids. Based on the evidence included 26 
in this review, low dose opioids can be considered as safe treatment for chronic breathlessness in the 27 
context of good clinical care and appropriate monitoring. However, the studies that have been 28 
conducted are mostly of low quality, short duration and not designed to assess the effect of low dose 29 
opioids on respiratory adverse effects. A long term, well-powered randomized controlled trial, like 30 
the MORDYC study, is needed. Moreover, including a common respiratory outcome set in all trials of 31 
opioids for breathlessness, so that a more robust synthesis could be conducted, is recommended. 32 
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